NASDAQ
65.16USD
-2.86 (-4.20%)
We have scored 6 news catalysts on Bright Minds Biosciences Inc. (DRUG) over the past 12 months. The biggest single-day move next to one of them came Jan 6, 2026, when DRUG closed +16.5%: “Bright Mind Biosciences shares surge on positive epilepsy drug trial results”. Coverage across the window leans positive (average ticker sentiment +0.43). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Latest scored catalyst for DRUG: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market cap
637.7M
P/E
—
EPS
—
Beta
0.09
52W range
39.697-123.75
Day range
64.51–69.06
Open
67.84
Prev close
68.02
Volume
93K
Avg volume
265.8K
Dividend
0.00
IPO
2021-03-22
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Bright Minds Biosciences Inc. — not a sector bucket. Click an edge to see the articles that established the link.
